Navigation Links
EntreMed Reports Fourth Quarter and Year-End 2008 Financial Results

ROCKVILLE, Md., March 12 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for the three months and twelve months ended December 31, 2008.

(Logo: )

For fiscal year 2008, revenues were $7.5 million versus $7.4 million for 2007. For the year ended December 31, 2008, the Company reported a net loss of ($24.9 million) or ($0.29) per share, versus ($23.4 million), or ($0.28) per share, for fiscal year 2007. As of December 31, 2008, the Company had cash and short-term investments of approximately $24 million.

Revenues for the fourth quarter ended December 31, 2008 were $4.0 million compared to $3.9 million for the fourth quarter ended December 31, 2007. The Company reported a net loss of ($2.8 million), or ($.04) per share for the three months ended December 31, 2008. This compares with a net loss of ($4.0 million), or ($0.05) per share for the fourth quarter 2007.

Kathy R. Wehmeir-Davis, Principal Accounting Officer, commented, "Financial results for 2008 are reflective of the Company's decision to realign its financial and human resources to focus primarily on the clinical development of our Aurora A and angiogenic kinase inhibitor, ENMD-2076, for the treatment of cancer. As a result of the realignment, the Company reduced its workforce by approximately sixty percent, which resulted in a fourth quarter charge for severance and related benefits of approximately $1.7 million. Our fourth quarter 2008 revenue was consistent with fourth quarter revenue in 2007."

Ms. Wehmeir-Davis continued, "For 2008, we recorded $7.5 million in royalty revenue from Celgene's sales of Thalomid(R), a small increase over our 2007 royalty revenues of $7.4 million. Research and development expenses decreased in 2008 by approximately $3.7 million, which results primarily from discontinuing clinical development of 2ME2 (Panzem(R) NCD) for oncology and winding down of manufacturing and clinical trial operations with our other product candidates. Also reflected in the operating results for 2008 is a non-cash charge of $2.0 million, which represents a purchase price adjustment milestone triggered by the dosing of the first patient in a clinical trial for ENMD-2076, which was paid in stock to Miikana shareholders. In 2009, we expect our revenues will remain consistent with 2008 and our cash expenses will decrease significantly compared to 2008 as we focus primarily on the development of ENMD-2076."

Executive Chairman of the Board, Michael M. Tarnow commented, "We ended 2008 on solid financial footing and continue to make progress on the implementation of our realigned strategy, which focuses specifically on the clinical development of our priority program, ENMD-2076. The Board remains confident that we have the right team in place to execute on this accelerated development strategy and the financial resources to accomplish our current and planned operational objectives well into 2010. We will continue to curtail all costs not associated with the development of ENMD-2076 in order to further preserve our financial resources."

In lieu of a fourth quarter and year end update call, up-to-date information regarding the Company, including our most recent Form 10-K filing and Letter from the Executive Chairman, can be found on our web site at

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company focusing primarily on the development of its priority program, ENMD-2076, for the treatment of cancer. ENMD-2076 is an Aurora A and angiogenic kinase inhibitor, which is currently in Phase 1 studies in patients with solid tumors and multiple myeloma. In addition, multiple Phase 1 and 2 clinical trials are ongoing for MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, and ENMD-1198, a novel tubulin-binding agent. The Company also has an approved IND application for Panzem(R) in the treatment of rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks patent, product liability, supply, competition relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, and other risks).

    Ginny Dunn
    Associate Director, Corporate
    Communications & Investor Relations
    EntreMed, Inc.

                                 ENTREMED, INC.
                          SUMMARY OF OPERATING RESULTS
                               Three Months Ended
                                  December 31,

                                             2008             2007

    Total revenues                      $  3,975,912     $  3,875,392

    Research and development            $  3,440,102     $  5,650,152

    General and administrative          $  2,489,947     $  1,978,982

    Net loss                            $ (2,547,552)    $ (3,767,496)

    Dividend on Series A
     convertible preferred stock        $   (251,250)    $   (251,250)

    Net loss attributable
     to common shareholders             $ (2,798,802)    $ (4,018,746)

    Net loss per share attributable to
     common shareholders
     (basic and diluted)                $      (0.04)    $      (0.05)

    Weighted average number of
     shares outstanding
     (basic and diluted)                  87,728,644       84,362,710

                            Twelve Months Ended
                                December 31,

                                             2008              2007

    Total revenues                     $   7,477,219     $   7,395,651

    Research and development           $  20,069,229     $  23,739,392

    General and administrative         $   7,764,532     $   7,386,570

    Acquired in-process R&D            $   2,000,000     $           -

    Net loss                           $ (23,862,028)    $ (22,411,121)

    Dividend on Series A
     convertible preferred stock       $  (1,005,000)    $  (1,005,000)

    Net loss attributable to
     common shareholders               $ (24,867,028)    $ (23,416,121)

    Net loss per share attributable to
     common shareholders
     (basic and diluted)               $       (0.29)    $       (0.28)

    Weighted average number of
     shares outstanding
     (basic and diluted)                  86,479,768        84,166,552

    Cash and Short-term Investments    $  24,291,173     $  47,748,191

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. EntreMed Reports Third Quarter 2007 Financial Results
6. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
7. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
8. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
9. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
10. EntreMed Reports First Quarter 2008 Financial Results
11. EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... CBD College is proud to announce that on ... accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join this ... colleges and universities in the state of California make the cut. CBD College is ...
(Date:11/27/2015)... San Francisco, California (PRWEB) , ... November 27, 2015 , ... ... 1969 Janis Joplin Ann Arbor Michigan boxing style concert posters. This is one of ... 1969 at the Canterbury House at the University of Michigan in Ann Arbor. The ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they also think ... during the Black Friday and Cyber Monday massage chair sales to receive ... high and low to find the best massage chair deals, they can see all ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... of workshops to discuss bioavailability and the need to integrate dose form selection ... in collaboration with OBN, the membership organization supporting and bringing together the UK’s ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... opinion process, participated in the 61st annual Employee Benefits Conference. The Employee Benefits ... place Sunday, November 8th through Wednesday, November 11th, 2015. The conference was held ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 ... the potential to use SyMRI to find optimal contrast weighting ... brain tumor metastases, and has signed a research agreement with ... at the hospital. Using SyMRI, it is possible to generate ... parameter settings after the patient has left, thus making it ...
(Date:11/26/2015)... ) has ... Future Horizons and Growth Strategies in the ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> ) has announced the ... and Growth Strategies in the French Drugs ...
(Date:11/26/2015)... Research and Markets ( ) has announced the ... Type (Dressings, Therapy Devices, Active Wound Care), Application (Surgical ... Geography - Global Forecast to 2020" report to ... --> The purpose of this report is to ... advanced wound care market. It involves deep dive analysis ...
Breaking Medicine Technology: